A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

Trial Details

NCT ID
NCT05389293
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Mosunetuzumab
  • Zanubrutinib
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292

Key Eligibility Criteria

  • Signed Informed Consent Form(s)
  • Ability to comply with all the study-related procedures, in the investigator's judgement
  • Age 18 years or older
  • ECOG performance Status of 0, 1, or 2 \[Appendix 2\]

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →